U.S. FDA again expands usage of Regeneron eye drug Eylea
March 25, 2015 at 11:17 AM EDT
March 25 (Reuters) - U.S. health regulators on Wednesday approved Regeneron Pharmaceuticals Inc's big-selling eye drug Eylea to treat diabetic retinopathy, the most common diabetic eye disease and a leading cause of blindness in adults.
